TRCT
NAMS icon

Tower Research Capital (TRC)’s NewAmsterdam Pharma NAMS Stock Holding History

Tower Research Capital (TRC)’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$153K Buy
4,500
+3,302
+276% +$109K ﹤0.01% 1893
2026
Q1 		$38.3K Buy
1,198
+255
+27% +$8.31K ﹤0.01% 2975
2025
Q4 		$33.1K Sell
943
-2,029
-68% -$73.8K ﹤0.01% 2734
2025
Q3 		$84.5K Buy
2,972
+2,424
+442% +$58.1K ﹤0.01% 2135
2025
Q2 		$9.92K Sell
548
-164
-23% -$2.99K ﹤0.01% 3974
2025
Q1 		$14.6K Sell
712
-585
-45% -$13K ﹤0.01% 3282
2024
Q4 		$33.3K Sell
1,297
-6,485
-83% -$138K ﹤0.01% 2827
2024
Q3 		$129K Buy
+7,782
New +$135K ﹤0.01% 2026
2023
Q1 		– Sell
-88
Closed -$1K – 6119
2022
Q4 		$1K Buy
+88
New +$875 ﹤0.01% 5633

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Tower Research Capital (TRC)'s NAMS Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its NewAmsterdam Pharma (NAMS) stake by 276% in Q2 2026, buying an estimated $109K and bringing the position to 4,500 shares worth $153K. The position accounts for ﹤0.01% of the portfolio, ranked #1893.

Tower Research Capital (TRC) first reported a position in NAMS in Q4 2022 and has held it in 9 quarters since. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • Tower Research Capital (TRC) held 4,500 shares of NewAmsterdam Pharma worth $153K as of Q2 2026.
  • Tower Research Capital (TRC) bought 3,302 NewAmsterdam Pharma shares in Q2 2026, an estimated $109K.
  • NewAmsterdam Pharma made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #1893 holding.
  • Tower Research Capital (TRC) first reported a position in NewAmsterdam Pharma in Q4 2022 and has held it in 9 quarters since.
  • 194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.